PMID: 2126144Jan 1, 1990Paper

A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression

Progress in Neuro-psychopharmacology & Biological Psychiatry
D RothD V Sheehan

Abstract

1. The efficacy of fluvoxamine is compared to that of desipramine in a multicenter double blind placebo controlled six-week flexible dose trial of 90 outpatients with major depressive disorder. 2. Although overall drug effects were relatively weak, there were trends suggesting separation of both active drugs from placebo at week six. Both drugs were well tolerated. 3. Studies of major depression ought to be designed to last 8-10 weeks in order to demonstrate placebo active drug differences and the stability of such a difference should it occur in the first six weeks.

References

Aug 1, 1977·British Journal of Pharmacology·V ClaassenP Placheta
Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·R W Fuller, D T Wong
Dec 16, 1986·European Journal of Pharmacology·T J WanderE Richelson
Jan 1, 1974·Behavioral Science·L R DerogatisL Covi
Jun 1, 1968·The British Journal of Psychiatry : the Journal of Mental Science·B J Carroll
Dec 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·D M ShawE G Eccleston
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Dec 1, 1984·Journal of Affective Disorders·K R NortonE S Paykel
Mar 1, 1984·Archives of General Psychiatry·F M QuitkinP J McGrath
Jan 1, 1983·British Journal of Clinical Pharmacology·B SaletuP Rajna
Jan 1, 1983·British Journal of Clinical Pharmacology·J D GuelfiP Pichot
Jan 1, 1983·British Journal of Clinical Pharmacology·J E De WildeJ S Wakelin
Jan 1, 1983·British Journal of Clinical Pharmacology·T M ItilS T Michael
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·B S Coleman, B A Block
May 1, 1982·The British Journal of Psychiatry : the Journal of Mental Science·P R RowanR R Parker
Dec 1, 1981·Archives of General Psychiatry·H Y MeltzerB J Tricou
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH

❮ Previous
Next ❯

Citations

Nov 8, 2006·Archives of General Psychiatry·Matthew J TaylorZubin Bhagwagar
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N BrunelloG Racagni
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·N P NairT E West
Mar 13, 1993·BMJ : British Medical Journal·F SongJ Mason
Mar 27, 2009·Psychotherapy and Psychosomatics·Bret R RutherfordSteven P Roose
Dec 9, 2010·Biological & Pharmaceutical Bulletin·Yasuhiro KatohHisakuni Hashimoto
Nov 25, 2003·The Annals of Pharmacotherapy·Pieter StolkThomas R Einarson
Jul 20, 2007·The Cochrane Database of Systematic Reviews·J R GeddesJ Boynton
Feb 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfG Lewis
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Ichiro M OmoriToshi A Furukawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.